利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.021 秒)

    MUCIN ANTIGEN VACCINE
    1.
    发明申请
    MUCIN ANTIGEN VACCINE 有权
    MUCIN ANGGEN VACCINE

    公开(公告)号：US20140073045A1

    公开(公告)日：2014-03-13

    申请号：US13948573

    申请日：2013-07-23

    申请人： MicroVAX, LLC

    发明人： Yucheng Tang ,  Albert Deisseroth

    IPC分类号： C12N15/85

    CPC分类号： A61K39/0011 ,  A61K9/127 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/6031 ,  C07K14/4727 ,  C07K14/70578 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/85 ,  C12N15/86 ,  C12N2710/10043

    摘要： Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.

    摘要翻译： 提供了用于产生对粘蛋白的免疫应答的表达载体。 载体包含编码可分泌多肽的转录单位，所述多肽包含分泌信号，粘蛋白抗原和CD40配体。 还提供了通过施用有效量的载体产生针对表达粘蛋白的细胞的免疫应答的方法。 还提供了通过施用有效量的载体来产生针对个体中表达粘蛋白的癌细胞的免疫应答的方法。 还提供了通过施用有效量的载体克服对粘蛋白自身抗原的无反应性的方法。

    Mucin antigen vaccine
    2.
    发明授权
    Mucin antigen vaccine 有权
    粘蛋白抗原疫苗

    公开(公告)号：US08501707B2

    公开(公告)日：2013-08-06

    申请号：US13662616

    申请日：2012-10-29

    申请人： MicroVAX, LLC

    发明人： Yucheng Tang ,  Albert Deisseroth

    IPC分类号： C07H21/04 ,  A61K39/00 ,  A61K39/12

    CPC分类号： A61K39/0011 ,  A61K9/127 ,  A61K48/00 ,  A61K48/005 ,  A61K2039/6031 ,  C07K14/4727 ,  C07K14/70578 ,  C07K2319/00 ,  C12N7/00 ,  C12N15/85 ,  C12N15/86 ,  C12N2710/10043

    摘要： Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.

    摘要翻译： 提供了用于产生对粘蛋白的免疫应答的表达载体。 载体包含编码可分泌多肽的转录单位，所述多肽包含分泌信号，粘蛋白抗原和CD40配体。 还提供了通过施用有效量的载体产生针对表达粘蛋白的细胞的免疫应答的方法。 还提供了通过施用有效量的载体来产生针对个体中表达粘蛋白的癌细胞的免疫应答的方法。 还提供了通过施用有效量的载体克服对粘蛋白自身抗原的无反应性的方法。

    VACCINE DIRECTED TO INDUCTION OF IMMUNE RESPONSE TO PROTEIN AND GLYCOLIPID ANTIGENS OF BACTERIAL CELLS THROUGH INTERACTION OF CD40L/CD40 RECEPTOR AXIS WITH COMPLEX OF GLYCOLIPID/CD1d RECEPTOR IN NKT CELLS AND IN DENDRITIC CELLS
    3.
    发明申请
    VACCINE DIRECTED TO INDUCTION OF IMMUNE RESPONSE TO PROTEIN AND GLYCOLIPID ANTIGENS OF BACTERIAL CELLS THROUGH INTERACTION OF CD40L/CD40 RECEPTOR AXIS WITH COMPLEX OF GLYCOLIPID/CD1d RECEPTOR IN NKT CELLS AND IN DENDRITIC CELLS 审中-公开

    公开(公告)号：US20200046820A1

    公开(公告)日：2020-02-13

    申请号：US16507432

    申请日：2019-07-10

    申请人： Albert B. Deisseroth

    发明人： Albert B. Deisseroth

    IPC分类号： A61K39/02 ,  A61K39/39

    摘要： A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the α-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.

    TAA/CD4OL composition/vaccine for malaria
    5.
    发明授权
    TAA/CD4OL composition/vaccine for malaria 有权

    公开(公告)号：US10183067B1

    公开(公告)日：2019-01-22

    申请号：US15587777

    申请日：2017-05-05

    申请人： MicroVAX, LLC

    发明人： Albert B. Deisseroth

    IPC分类号： A61K39/00 ,  A61K39/015 ,  C07K14/445

    摘要： Provided are compositions and methods of selecting at least three fragments one each from three domains of the malarial CSP for generating antigen specific CD8 effector T cells and non-cross reacting neutralizing antibody immune responses to the malarial parasite, which when administered prevent an infection of a human being when bitten by a malaria infected mosquito. The composition and method comprises priming an individual by administering a mixture of one or more adenoviral expression vectors encoding one or more fusion proteins, which comprises the malarial CSP antigen fragments linked to the extracellular domain of the CD40 ligand. The adenoviral expression vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing selected malarial sporozoite CSP antigen fragments linked to the CD40 ligand to block the attachment to or infection of the human liver cell(s) by the malarial sporozoite.

    Composition and method against C-difficile
    6.
    发明授权
    Composition and method against C-difficile 有权

    公开(公告)号：US10149899B1

    公开(公告)日：2018-12-11

    申请号：US15375455

    申请日：2016-12-12

    申请人： Albert B. Deisseroth

    发明人： Albert B. Deisseroth

    IPC分类号： A61K39/08 ,  C12N9/10 ,  C07K14/705 ,  A61K39/00

    摘要： This two-step method used in the Clostridium difficile toxin transport is a unique method of delivery. The use of a vaccine (TAA/ecdCD40L) for the interdiction of this two-step delivery toxin system to reduce cell death and the death of human subjects is believed to be unique in the area of neutralizing antibodies for protection against the lethal effects of an infectious agent. The proposed composition/vaccine strategy for C difficile is to combine and administer at the same time the two compositions/vaccines for Toxin A, the one composition/vaccine for Toxin B and the one vaccine for CDTb to determine the effect of mixing these compositions/vaccines on protecting mice from a lethal dose of C difficile. This is believed to be the first time that two different tandem repeats from the contact of a ligand with its cellular receptor have been used to prevent binding of the ligand to its cellular receptor.

    Methods for generating immunity to antigen
    9.
    发明授权
    Methods for generating immunity to antigen 有权
    产生免疫抗原的方法

    公开(公告)号：US08828957B2

    公开(公告)日：2014-09-09

    申请号：US11009533

    申请日：2004-12-10

    申请人： Albert Deisseroth ,  Yucheng Tang ,  Wei-Wei Zhang ,  Xiang-Ming Fang

    发明人： Albert Deisseroth ,  Yucheng Tang ,  Wei-Wei Zhang ,  Xiang-Ming Fang

    IPC分类号： A61K48/00 ,  A61K38/00

    CPC分类号： C07K14/4748 ,  A61K39/0011 ,  A61K2039/545 ,  A61K2039/6031 ,  C07K14/70578 ,  C12N15/86 ,  C12N2710/10343

    摘要： Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.

    摘要翻译： 提供了产生对抗原的免疫应答的方法。 该方法包括通过施用编码抗原的表达载体来引发个体。 载体包含编码可分泌融合蛋白的转录单元，含有抗原和CD40配体的融合蛋白。 使用含有抗原和CD40配体的融合蛋白的施用用于增强仅通过单独载体给药获得的免疫应答。 本发明的方法可用于产生针对表达肿瘤抗原例如粘蛋白或人乳头状瘤病毒肿瘤抗原的癌症的免疫应答，并产生针对感染因子的免疫应答。 还提供了同时产生表达载体和融合蛋白的方法。